Drug induced liver injury (DILI) is a relatively rare hepatic condition in response to the use of
medications, illegal drugs, herbal products or dietary supplements. It occurs in susceptible …

Renal or hepatic impairment is a common comorbidity for patients with cancer either
because of the disease itself, toxicity of previous anticancer treatments, or because of other …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death globally, and its
prevalence and impact are even more profound because sorafenib is the only systemic …

Besides drug reactions, there are multiple potential causes of abnormal liver tests that may
be important in the population being considered for chemotherapy (Table 1). 129.167 …

The number of chemotherapy options and combination regimens for a multitude of
malignancies has vastly increased in the last few decades. An unfortunate consequence of …

Design and execution of clinical trials use definitions and criteria to permit a homogeneous
study development avoiding heterogeneous decisions by investigators at different sites …

Background There are no clear predictors clinicians can use to determine who is more likely
to experience dose-limiting toxicity (DLT) in phase I chemotherapy clinical trials. Many …

Introduction: We conducted a systematic literature review to assess the utility of liver function
assessments for predicting disease prognosis and response to systemic anticancer therapy …

Hepatocellular carcinoma (HCC) is the third largest cause of cancer-related death behind
only lung and colon cancers. 1 Overall, one third of cirrhotic patients will develop HCC …

TO THE EDITOR: Cainap et al 1 reported results of a randomized, open-label phase III trial
evaluating linifanib versus sorafenib in patients with advanced hepatocellular carcinoma …